Search Results

You are looking at 61 - 70 of 1,396 items for :

  • "carcinoma" x
  • Refine by Access: All x
Clear All
Full access

Treatment Options for Merkel Cell Carcinoma

Samuel W. Beenken and Marshall M. Urist

No benefits or funds were received in support of this study. References 1 Toker C . Trabecular carcinoma of the skin . Arch Dermatol 1972 ; 105 : 107 – 110 . 2 Medina-Franco H Urist MM Fiveash J . Multimodality

Full access

Geographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study

En Cheng, Peiyin Hung, and Shi-Yi Wang

Background Hepatocellular carcinoma (HCC) is the dominant histologic type of liver cancer, affecting approximately 20,000 Americans annually. 1 HCC incidence and mortality have been increasing in the United States during the past 3 decades. 2

Full access

Conditional Survival of Patients With Nonmetastatic Renal Cell Carcinoma: How Cancer-Specific Mortality Changes After Nephrectomy

Carlotta Palumbo, Francesco A. Mistretta, Sophie Knipper, Angela Pecoraro, Zhe Tian, Shahrokh F. Shariat, Fred Saad, Claudio Simeone, Alberto Briganti, Alessandro Antonelli, and Pierre I. Karakiewicz

-up have a higher probability of remaining disease-free. 1 However, the magnitude of improved survival is difficult to estimate. Two studies 2 , 3 address cancer-specific CS in patients with nonmetastatic renal cell carcinoma (nmRCC): one is a population

Full access

CRE24-049: Extrapulmonary Small Cell Carcinoma of Gallbladder Presenting as Acute Cholecystitis

Cindy Iwuagwu, Sesha Sai Kanakamedala, Sarah Tinsley, and Jamal Mohsin

Introduction: Small cell carcinoma (SCC) of the gallbladder is a rare and highly aggressive malignancy, characterized by early metastasis and a grim prognosis. Patients often present aggressive symptoms at an advanced stage of the disease

Full access

Patients With cT1N0M0 Oral Squamous Cell Carcinoma Benefit From Elective Neck Dissection: A SEER-Based Study

Alimujiang Wushou, Meng Wang, Feiluore Yibulayin, Lei Feng, Meng-meng Lu, Yuan Luo, Hui Liu, and Zhi-cheng Yang

Background Oral squamous cell carcinoma (OSCC) is among the most common cancers worldwide, with approximately 369,000 new cases reported in 2012, and increasing each year. 1 As presented in the NCCN Clinical Practice Guidelines in

Full access

Biallelic TSC2 Mutations in a Patient With Chromophobe Renal Cell Carcinoma Showing Extraordinary Response to Temsirolimus

Pablo Maroto, Georgia Anguera, Juan Maria Roldan-Romero, Maria Apellániz-Ruiz, Ferran Algaba, Jacqueline Boonman, Mark Nellist, Cristina Montero-Conde, Alberto Cascón, Mercedes Robledo, and Cristina Rodríguez-Antona

Chromophobe renal cell carcinoma (chRCC) is the third most frequent kidney cancer histologic subtype, accounting for approximately 5% of all RCC cases. At diagnosis, chRCC is generally confined to the kidney but can metastasize. At advanced stages

Full access

CRE24-036: Liver-ing on a Prayer: A Rare Case of Hepatocellular Carcinoma With Metastasis to the Thyroid

Rachel Truong, Odelvys Granela, Shelby Ploucher, Alyssa Obermiller, T. Van Anh, Brian Shaw, and Jacqueline N. Kropf

Liver cancer is thought to be the sixth most diagnosed cancer and is among the top five causes of cancer death globally. Hepatocellular carcinoma (HCC) accounts for up to 90% of primary liver neoplasms in adults. The incidence of thyroid

Full access

Liver Transplantation for Hepatocellular Carcinoma: An Update

Jean F. Botha and Alan N. Langnas

. 3. Penn I . Hepatic transplantation for primary and metastatic cancers of the liver . Surgery 1991 ; 110 : 726 – 735 . 4. Iwatsuki S Starzl TE Sheahan DG . Hepatic resection versus transplantation for hepatocellular carcinoma

Full access

Thyroid Carcinoma

H. Lee Moffitt Cancer Center & Research Institute at the University of South Florida

Although thyroid carcinoma is relatively uncommon, approximately 33,550 new cases will be diagnosed in the United States in 2007. It occurs 2 to 3 times more often in women than in men, and with the incidence increasing by 4% per year, it is currently the eighth most common malignancy diagnosed in women. Although it occurs more often in women, mortality rates are higher for men, probably because they are usually older at the time of diagnosis (65–69 years vs. 50–54 years in women). Interestingly, the incidence of thyroid carcinoma increased almost 240% between 1950 and 2000, but mortality rates decreased more than 44%. Important updates to the 2007 guidelines include revised criteria for categorizing disease, revised recommendation for thyroid-stimulating hormone–stimulated thyroglobulin in some cases, and expanded CT recommendations for anaplastic carcinoma.

For the most recent version of the guidelines, please visit

Full access

Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Robert I Haddad, Lindsay Bischoff, Douglas Ball, Victor Bernet, Erik Blomain, Naifa Lamki Busaidy, Michael Campbell, Paxton Dickson, Quan-Yang Duh, Hormoz Ehya, Whitney S. Goldner, Theresa Guo, Megan Haymart, Shelby Holt, Jason P. Hunt, Andrei Iagaru, Fouad Kandeel, Dominick M. Lamonica, Susan Mandel, Stephanie Markovina, Bryan McIver, Christopher D. Raeburn, Rod Rezaee, John A. Ridge, Mara Y. Roth, Randall P. Scheri, Jatin P. Shah, Jennifer A. Sipos, Rebecca Sippel, Cord Sturgeon, Thomas N. Wang, Lori J. Wirth, Richard J. Wong, Michael Yeh, Carly J. Cassara, and Susan Darlow

Overview For the United States population, the lifetime risk of being diagnosed with thyroid carcinoma is 1.2%. 1 It is estimated that approximately 43,800 new cases of thyroid carcinoma will be diagnosed in the United States in 2022. 2 The